RxDoctor Payments Data

Kendra Ivy, OD

Optometrist · Sedona, AZNPI 1720574619

Payments from drug & device makers

$551in general payments, 2019–2025

Across 18 payments — averaging $30.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$108
  • Bausch & Lomb Americas Inc.$94
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$84
  • AbbVie$74
  • Mallinckrodt Hospital Products Inc.$38
  • Johnson & Johnson Vision Care, Inc.$27
  • plus $127 from 6 others

What the payments were for

  • Food & beverage$53296%
  • Gifts$194%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$551 in reported general payments places this provider in the 40th percentile of 1,134 optometrist providers in Arizona.

See all optometrist providers in Arizona

Medicare billing

Part B allowed, 2024
$245,991
Medicare patients
824
Services billed
3,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine12$14,052
Lotemax SmLoteprednol Etabonate30$11,078
LumiganBimatoprost15$10,072
VyzultaLatanoprostene Bunod17$9,155
Bromfenac Sodium19$5,223
Travoprost27$5,027
Latanoprost358$4,056
Timolol Maleate85$3,849
Ketorolac Tromethamine129$3,062
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat73$1,812
Difluprednate17$1,636
Doxycycline Monohydrate30$897
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha74$806
MoxifloxacinMoxifloxacin Hcl26$750
Brimonidine Tartrate55$685

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$74$24,12427 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm$84$11,07830 claims
Bausch & Lomb Americas Inc.Vyzulta$94$9,15517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,134 optometrist providers in Arizona.

Other optometrist in Sedona

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →